ArticleAmerican heart journal plus : cardiology research and practice2025
Prognostic impact of cardiac dysfunctions in patients with ST-segment elevation myocardial infarction.
Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence and impact of cardiac dysfunctions after ST-segment elevation myocardial infarction (STEMI) are not understood. We aimed to characterize the prevalence of follow-up systolic and diastolic dysfunction and their associations with long-term outcomes after STEMI. Methods and results: This sub-study of the DANAMI-3 trial included 542 patients with STEMI. Cardiac magnetic resonance (CMR)-defined systolic/diastolic impairment was applied to define systolic/diastolic dysfunction. Systolic dysfunction was defined as left ventricular ejection fraction (LVEF) < 50 %, and diastolic dysfunction as peak filling rate/end-diastolic volume (PFR/EDV) ≤ 2.55 by CMR three months after STEMI. The primary outcome was a composite of all-cause mortality and hospitalization for heart failure. Secondary outcomes were individual components of the primary outcome. During a median follow-up of 10.5 years, 103 patients died or were hospitalized for heart failure. A total of 101 and 232 patients had systolic and diastolic dysfunction at three months. Cox regression showed that LVEF was significantly associated with the outcomes, while PFR/EDV was not associated with any outcome. Systolic dysfunction (LVEF<50 %) was associated with the primary endpoint (adjusted hazards ratio [HR] 2.73), all-cause mortality (aHR 2.26), and hospitalization for heart failure (aHR 7.87). The incidences of isolated diastolic dysfunction, isolated systolic dysfunction and both cardiac dysfunctions were 150, 19 and 82. Patients with isolated systolic dysfunction and both dysfunctions were associated with the outcomes. Conclusions: Cardiac dysfunctions derived from CMR-defined systolic/diastolic impairment showed in about half of the three-month STEMI-survivors. Systolic dysfunction regardless of diastolic dysfunction is a significant predictor of long-term outcomes after STEMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.